secwatch.observer — SEC 8-K summary
======================================

Issuer:     CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)
CIK:        0001801170
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0001801170-24-000089
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clover Health names Peter Kuipers as CFO; targets adjusted EBITDA profitability in 2024
--------------------------------------------------------------------------------

- Peter Kuipers appointed CFO effective after Q1 2024 10-Q filing; succeeds interim CFO Terrence Ronan.
- Kuipers previously CFO at Omnicell (OMCL), helped grow revenue from $485M to $1.3B.
- Employment terms: base salary $525k, target bonus 95% of base, $5M RSU grant (25% vest 1yr, remainder quarterly).
- Company reiterates goal to achieve adjusted EBITDA profitability in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1801170/000180117024000089/0001801170-24-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1801170/000180117024000089/clov-20240422.htm
  HTML page:      https://secwatch.observer/filing/0001801170-24-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer